91ÊÓƵרÇø

2¡¢²õ³Ü²¹²Ô±ô³Ü´Ç²ú´Ç³ú³Ü´Ç³ú³ó³Ü³Ù¾±£¡±ô¾±³Ü»å¾±²Ô²µ°ì²¹²Ô³ú³ó³Ü´Ç³ó²¹´Ç³æ¾±²¹´Ç£¬²â²¹²Ô²µ³ú³ó³Ü´Ç²õ³ó±ð²Ô²µ²â¾±²Ô·É±ð²Ô£¬

2022-02-08 23:49¡¤½¨(Jian)°²(An)ÀÏ(Lao)³Â(Chen)

donglixitong£¬xinyidaituguanL PRO 380TSIsiquR-Linezhizunbandazaigaogonglv2.0Tfadongji£¬zuidagonglvwei162qianwa£¬chuandongxitongpipei7sushishishuanglihebiansuxiang£¬peibeishishisiquxitong¡£ciwai£¬xinyidaituguanL PROhuantigongdigonglv2.0Tfadongji£¬zuidagonglvwei137qianwa£¬chuandongxitongpipei7sushishishuanglihebiansuxiang¡£jinqi£¬sitaigengshichuanyansiqi¡£

л(³Ý¾±±ð)²¨(µþ´Ç)µÂ(¶Ù±ð)ÔÚ(´Ü²¹¾±)ÏÄ(³Ý¾±²¹)Áª(³¢¾±²¹²Ô)Èü(³§²¹¾±)ÖÐ(´Ü³ó´Ç²Ô²µ)Õ¹(´Ü³ó²¹²Ô)ÏÖ(³Ý¾±²¹²Ô)³ö(°ä³ó³Ü)ÁË(³¢¾±²¹´Ç)·Ç(¹ó±ð¾±)³£(°ä³ó²¹²Ô²µ)¾ª(´³¾±²Ô²µ)ÈË(¸é±ð²Ô)µÄ(¶Ù±ð)±È(µþ¾±)Èü(³§²¹¾±)¡°Í³(°Õ´Ç²Ô²µ)ÖÎ(´Ü³ó¾±)Á¦(³¢¾±)¡±£¬Æ®(±Ê¾±²¹´Ç)ÒÝ(³Û¾±)µÄ(¶Ù±ð)Çò(²Ï¾±³Ü)·ç(¹ó±ð²Ô²µ)ÉÍ(³§³ó²¹²Ô²µ)ÐÄ(³Ý¾±²Ô)ÔÃ(³Û³Ü±ð)Ä¿(²Ñ³Ü)£¡

Âéɽ´úµÄĸÇ×ÁÖÊÏ£¬ÊÇÂéÀϺºÔÚÊÀµÄʱºòÓýö´æµÄÇ®´ÓÍâµØÂòµÄÒ»¸öϱ¸¾£¬ÒòΪµ±µØÈ˾õµÃÂéÀϺº»á͵¶«Î÷£¬Ã»ÓÐÈËÔ¸Òâ¼Þ¸øËû£¬»¹ËµË­¼Þ¸øËûÕâ±²×ӾͻᵹѪù¡£µ«ÊÇ£¬ÔÚ¾­Óª¹«Ë¾Ê±£¬Ö»×öºÃÔËÓªÊÇÔ¶Ô¶²»¹»µÄ£¬»¹Òª¼°Ê±´´Ð¡¢¼°Ê±µ÷Õû£¬Õâ¹Øϵµ½¹«Ë¾µÄ³É°Ü¡£ÂåÀöËþ_¹ÜÏþ·å_¸ßÒôÖÊÔÚÏßÊÔÌý_ÂåÀöËþ¸è´Ê|¸èÇúÏÂÔØ_¿á¹·...¶«¸ç¸¨Öú°É - ¾«Ñ¡ÓÅÖʵÄÓÎÏ·,È«Ã渲¸Ç¸÷ÀàÓÎϷƽ̨...

ÈçºÎÇø·Ö·ÇµäÐÍCMLÓëÆäËû¹ÇËèÔöÖ³ÐÔÖ×ÁöÔ­´´2020-09-12 17:53¡¤Ò½ÂöͨѪҺ¿Æ×÷ÕߣºÀ¶¾¨Ïþ»¢±¾ÎÄΪ×÷ÕßÊÚȨҽÂöͨ·¢²¼δ¾­ÊÚȨÇëÎðתÔطǵäÐÍÂýÐÔËèϵ°×Ѫ²¡(aCML)BCR-ABL1(£­)ÊÇÒ»ÖÖº±¼ûµÄѪҺ¶ñÐÔÖ×ÁöÊôÓÚWHO¹ÇËèÖ×Áö·ÖÀàÖеĹÇËèÔöÉúÒì³£/¹ÇËèÔöÖ³ÐÔÖ×Áö(MDS/MPN)aCML×î³õ±»ÃüÃûΪ·ÇµäÐÍÐÎʽµÄÂýÐÔËèϵ°×Ѫ²¡(CML)¼¸Ê®ÄêÀ´aCMLµÄÕï¶Ï±ê×¼·¢ÉúÁËÏÔÖø±ä»¯È»¶øaCMLµÄÕï¶Ïȱ·¦ÌØÕ÷ÐÔ¶ÔÆä·Ö×Ó»ùÒòͼÆ×µÄÈÕÒæÁ˽âÓÐÖúÓÚÇø·ÖaCMLÓëÆäËûMDS/MPNºÍMPNsÒÔ±ãÔçÆÚÆô¶¯ÖÎÁƺ͸ÄÉÆÔ¤ºóaCMLµÄÁÙ´²ºÍÐÎ̬±íÐÍaCML»¼Õß±íÏÖ³ö¹ÇËèÔöÉúÌØÕ÷°üÀ¨°×ϸ°ûÔö¶àºÍÆ¢Ö×´ó¿É°éÓÐƶѪºÍѪС°å¼õÉÙWBC¼ÆÊý¡Ý13¡Á109/LÍâÖÜѪÖдæÔÚÖÁÉÙ10%µÄδ³ÉÊìÁ£Ï¸°û£¨°üÀ¨ÔçÓ×Á£Ï¸°û¡¢ÖÐÓ×Á£Ï¸°ûºÍÍíÓ×Á£Ï¸°û£©ÒÔÖضÈÁ£Ï¸°ûÉú³ÉÕÏ°­ÎªÌØÕ÷²»´æÔÚµ¥ºËϸ°ûÔö¶à£¨ÍâÖÜѪµ¥ºËϸ°û<ѪҺ°×ϸ°ûµÄ10%ѪҺ¼ÆÊý< 1¡Á109/L£©ÍâÖÜѪÖеÄÊȼîÐÔÁ£Ï¸°û< 2%¹ÇËèºÍÍâÖÜѪÖÐԭʼϸ°û£¨°üÀ¨Ó×µ¥ºËϸ°û£©< 20%ÐÎ̬ѧÉÏaCMLÍâÖÜѪ±íÏÖΪÑÏÖØÁ£Ï¸°ûÒìÐÍÔöÉúÌØÕ÷ÐÔ±íÏÖ°üÀ¨ÖÐÐÔÁ£Ï¸°ûµÄȾɫÖʹý¶È¾Û¼¯ÒÔ¼°ºË·ÖÁÑÏóÒì³£ÈçºËµÍ·ÖÒ¶(¼ÙPelger-HuetºË)»ò¶à·ÖÒ¶°û½¬¿É³Ê¿ÅÁ£¼õÉÙÉõÖÁÒì³£Ôö´ó¹ÇËèϸ°û¹ý¶àÒÔÁ£Ï¸°ûΪÖ÷³ÊÃ÷ÏÔÒìÐÍÔöÉú°ëÊýÒÔÉϲ¡ÀýÓкìϵ·¢Óý²»Á¼ºÍÒ»¶¨³Ì¶ÈµÄ¾ÞºËϸ°û·¢Óý²»Á¼´ËÍâ¿É¼û²»Í¬³Ì¶ÈµÄÍøÓ²µ°°×ÏËάÔö¼ÓWHO 2016ÄêÌá³öµÄaCMLÒÔ¼°¾ßÓÐÏàËÆÌØÕ÷µÄËèϵÖ×ÁöÕï¶Ï±ê×¼×ܽá¼ûϱí×¢£ºaCML·ÇµäÐÍÂýÐÔËèÐÔ°×Ѫ²¡£»BM¹ÇË裻CMMLÂýÐÔÁ£µ¥ºËϸ°û°×Ѫ²¡£»ETÔ­·¢ÐÔѪС°åÔö¶àÖ¢£»MDS/MPN-RS-T¹ÇËèÔöÉúÒì³£/¹ÇËèÔöÉúÐÔÖ×Áö°é»·ÐÎÌúÁ£Ó×ϸ°ûºÍѪС°åÔö¶àÖ¢£»MDS/MPN-U¹ÇËèÔöÉúÒì³£/¹ÇËèÔöÉúÐÔÖ×Áö²»¿É·ÖÀࣻPVÕæÐÔºìϸ°ûÔö¶àÖ¢£»PBÍâÖÜѪaCMLµÄϸ°ûÒÅ´«Ñ§ÌØÕ÷¾¡¹Ü¸ù¾Ý¶¨ÒåaCMLȱ·¦·Ñ³ÇȾɫÌå¼°BCR-ABL1ÖØÅŵ«Ô¼Ò»°ëµÄaCML²¡Àý´æÔÚϸ°ûÒÅ´«Ñ§»û±ä°üÀ¨8ÈýÌå¡¢YȾɫÌåȱʧ¡¢20ºÅȾɫÌ峤±Û²¿·Öȱʧ(20q-)¡¢17ºÅµÈ±ÛȾɫÌå¡¢Éæ¼°12¡¢13¡¢14¡¢17ºÅȾɫÌåµÄȱʧºÍ¸´ÔÓºËÐÍÈ»¶øÕâЩϸ°ûÒÅ´«Ñ§Òì³£¾ù·ÇaCMLËùÌØÓÐÇÒÏ൱¶àµÄ²¡Àý£¨¸ß´ï80%£©¿É¾ßÓÐÕý³£µÄºËÐÍaCMLµÄ¸´·¢ÐÔ»ùÒòÍ»±äaCMLÖÐ×î³£¼ûµÄÍ»±ä»ùÒòÊÇASXL1¡¢NRAS¡¢SETBP1¡¢SRSF2ºÍTET2×î½üÑо¿±íÃ÷69%µÄaCML²¡ÀýÔÚ±í¹ÛÒÅ´«ÐÞÊλùÒòTET2¡¢IDH1/2¡¢DNMT3A¡¢EZH2ºÍ/»òASXL1ÖÐЯ´øÖÁÉÙÒ»ÖÖÍ»±äͼ1×ܽáÁËaCMLÖÐ×î³£¼ûµÄÍ»±äÈçºÎÕï¶ÏaCMLÕï¶ÏaCMLÓ¦»ùÓÚʶ±ðÆäÌØÕ÷ÐÔµÄÐÎ̬ѧ¡¢ÊµÑéÊÒºÍÒÅ´«Ñ§ÌØÕ÷Åųý¾ßÓÐÃ÷È·ÒÅ´«Ñ§¸Ä±äµÄÆäËûËèϵ¶ñÐÔÖ×Áö³õ²½¼ì²éÓ¦²àÖØÓÚÅųýBCR-ABL1Èںϸù¾Ý¶¨ÒåCML±ØÈ»´æÔÚBCR-ABL1Èں϶øaCMLÖÐÎÞ´ËÏÖÏó»¹Ó¦ÅųýÆäËû²¡ÀíÐÔ»ùÒòÍ»±äÈçPDGFRA¡¢PDGFRB¡¢FGFR1»òPCM1-JAK2ÈںϼøÓÚÕâЩÖØÅÅ¿ÉÄÜ´æÔÚÒÅ´«Ñ§ÒþÃسýÁ˺ËÐÍ·ÖÎöÔÚÈ·¶¨aCMLÕï¶Ï֮ǰÓ¦¿¼ÂÇFISH¼ì²â»òRNA-²âÐòÀ´ÅųýÉÏÊöÇé¿öPDGFRBÖØÅŵÄËèϵÖ×Áö»¼Õ߿ɱíÏÖΪMDS/MPNÑù±íÐÍÐÎ̬ѧÌØÕ÷ÓëaCMLÏàËÆÏÖÒÑÒâʶµ½PDGFRBÖØÅŵÄËèϵÖ×Áö¾ßÓзdz£¹ã·ºµÄ±íÐͲ¢²»¾ÖÏÞÓÚ°éÊÈËáÐÔÁ£Ï¸°ûÔö¶àÌØÕ÷µÄCMMLʶ±ðÖØÅÅ£¨ÈçPDGFRB/PDGFRA£©ÖÁ¹ØÖØÒªÒòΪÓëaCMLÏà±È¾ßÓÐÕâÀàÌØÕ÷µÄ¼²²¡¶ÔÀÒ°±ËἤøÒÖÖƼÁ£¨ÒÁÂíÌæÄᣩµÄÃô¸ÐÐÔ¸ßÔ¤ºó½ÏºÃÇø·ÖaCMLÓëijЩBCR-ABL1£¨-£©µÄMPNs £¨CNLÔ­·¢ÐÔ¹ÇËèÏËά»¯[PMF]£©ºÍMDS/MPN£¨CMMLºÍMDS/MPN-U£©¾ßÓÐÌôÕ½ÐÔMPN¼ÈÍùÊ·¿ÉÅųýaCMLµÄÕï¶Ï¹ÇËè»î¼ì·¢ÏÖµäÐ͵ÄMPNÐÎ̬ѧ½á¹û£¨ÓÈÆäÊÇÔÚûÓÐÏÔÖøÁ£Ï¸°û·¢Óý²»Á¼µÄÇé¿öÏ£©ºÍMPNÏà¹ØÍ»±ä£¨ÔÚJAK2¡¢CALR»òMPLÖУ©Ê±²»ÇãÏòaCMLÌáʾPMF¡¢ÕæÐÔºìϸ°ûÔö¶àÖ¢(PV)»òÔ­·¢ÐÔѪС°åÔö¶àÖ¢(ET)ÌáʾÐÔµÄÍ»±äÌØÕ÷£¨ÈçSETBP1/ETNK1Í»±ä£©ÇÒ¾ßÓзûºÏÕï¶Ï±ê×¼µÄÌØÕ÷ÓÐÖúÓÚ֤ʵaCMLÍâÖÜѪÖе¥ºËϸ°ûµÄ°Ù·Ö±ÈÊÇÇø·ÖaCMLºÍCMMLµÄÖØÒªÌØÕ÷ÔÚaCMLÖÐʼÖÕµÍÓÚ10%£¨ºÜÉÙ>2%£©ϸ°û»¯Ñ§È¾É«Èç·ÇÌØÒìÐÔõ¥Ã¸(NSE)ÓÐÖúÓÚÔÚÒÉÄѲ¡ÀýÖмì²âµ¥ºËϸ°ûÁíÒ»¸ö¸üÖ÷¹ÛµÄÐÎ̬ѧÇø±ðÊÇaCML´æÔÚ¸üÑÏÖصÄÁ£Ï¸°û·¢Óý²»Á¼¾¡¹Üȱ·¦ÆÀ¹À·¢Óý²»Á¼ÑÏÖس̶ȵľßÌåÖ¸ÄÏÐèÒª½øÐÐÌúȾɫÒÔÅųý°éÓл·ÐÎÌúÁ£Ó×ϸ°ûºÍѪС°åÔö¶àµÄMDS/MPN-RS-TÔÚÒÔÔöÖ³ÌØÕ÷ΪÖ÷ÇÒÒÔÖÐÐÔÁ£Ï¸°ûΪÖ÷µÄ»¼ÕßÖÐCSF3RÍ»±äӦǿÁÒÌáʾCNLÇø·ÖaCMLÓëMDS/MPN-U½ÏΪÀ§ÄÑaCML»¼ÕßµÄÖÐλWBC¼ÆÊýÏÔÖøÉý¸ßµ«·Ç¾ø¶ÔÌØÕ÷³ÖÐøÐÔµ¥ºËϸ°ûÔö¶àÌáʾCMMLTET2+SRSF2Í»±ä¶ÔCMML¾ßÓÐÏà¶ÔÌØÒìÐÔ¾¡¹ÜÁ½ÕßÔÚaCMLÖоù¿É¼ûÒ»ÖÖеÄaCMLÕï¶ÏÁ÷³ÌС½áÓÉÓÚ·¢²¡Âʵ͡¢Õï¶Ï±ê×¼²»¶Ï¸üкÍȱ·¦·Ö×ÓÒÅ´«Ñ§µÄÀí½â·ÇµäÐÍÂýÐÔËèϵ°×Ѫ²¡Ò»Ö±ÊÇÒ»ÖÖÄÑÒÔÕï¶ÏµÄMDS/MPNËæ×ŶԻùÒò×é´óÊý¾ÝµÄ²»¶ÏÍÚ¾òÒÑ·¢ÏÖSETBP1ºÍETNK1µÄ·´¸´Í»±ä¶ÔaCMLÓÐÌáʾ×÷ÓÿÉÒÔ½áºÏʵÑéÊÒºÍÐÎ̬ѧ½á¹ûÀ´Çø·ÖaCMLºÍÆäËû·Ñ³ÇÒõÐÔ¹ÇËèÔöÖ³ÐÔÖ×ÁöÈ»¶øÍ»±äµÄͬʱ·¢ÉúÊÇ·ñ»á¸Ä±äaCMLµÄ¼²²¡±íÐͺÍÖÎÁÆ·´Ó¦Éв»Ã÷È·²Î¿¼ÎÄÏ×£º1. Orazi A, Bennett JM, Bain BJ, et al. Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2017. pp. 87¨C89.2. Kantarjian HM, Keating MJ, Walters RS, et al. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 1986; 58:2023¨C2030.3. Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001; 19:2915¨C2926.4. Giri S, Pathak R, Martin MG, Bhatt VR. Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database. Ther Adv Hematol 2015; 6:308¨C312.5. Sadigh S, Hasserjian RP, Hobbs G. Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. Curr Opin Hematol. 2020;27(2):122-127.6. Itonaga H, Ota S, Ikeda T, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: a retrospective nationwide study in Japan. Leuk Res 2018; 75:50¨C57.7. Meggendorfer M, Haferlach T, Alpermann T, et al. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. Haematologica 2014; 99:e246.8. Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 2014; 123:2645 -2651.9. Patnaik MM, Barraco D, Lasho TL, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 2017; 92:542¨C548.10. Schwartz LC, Mascarenhas J. Current and evolving understanding of atypical chronic myeloid leukemia. Blood Rev 2019; 33:74¨C81.11. Faisal M, Stark H, Busche G, € et al. Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. Cancer Med 2019; 8:742¨C750.12. Zhang H, Wilmot B, Bottomly D, et al. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 2019; 134:867¨C879.13. Hasserjian RP. Illuminating neutrophilic myeloid neoplasms. Blood 2019; 134:846¨C848.14. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002; 107:113¨C122.15. Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 2014; 123:3574¨C3577.16. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120: 3080¨C3088.

ÉùÃ÷£º¸ÃÎĹ۵ã½ö´ú±í×÷Õß±¾ÈË£¬ËѺüºÅϵÐÅÏ¢·¢²¼Æ½Ì¨£¬ËѺü½öÌṩÐÅÏ¢´æ´¢¿Õ¼ä·þÎñ¡£